Skip to main content

Advertisement

SpringerLink
Log in

Genetics

Raynaud phenomenon: from GWAS to drug repurposing

  • News & Views
  • Published:

From Nature Reviews Rheumatology

View current issue Sign up to alerts

The identification of novel risk variants in the largest genome-wide association study of Raynaud phenomenon to date provides insights into the pathophysiology of the condition, including the potential role for α2A-adrenoceptors, and suggests opportunities for drug repurposing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Herrick, A. L. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat. Rev. Rheumatol. 8, 469–479 (2012).

    Article  CAS  PubMed  Google Scholar 

  2. Flavahan, N. A. A vascular mechanistic approach to understanding Raynaud phenomenon. Nat. Rev. Rheumatol. 11, 146–158 (2015).

    Article  PubMed  Google Scholar 

  3. Freedman, R. R. & Mayes, M. D. Familial aggregation of primary Raynaud’s disease. Arthritis Rheum. 39, 1189–1191 (1996).

    Article  CAS  PubMed  Google Scholar 

  4. Maudrell, A. & Proudman, S. M. in Raynaud’s Phenomenon: A Guide to Pathogenesis and Treatment 1st edn (eds Wigley, F. M. et al.) Ch. 3 (Springer New York, 2015).

  5. Hartmann, S. et al. ADRA2A and IRX1 are putative risk genes for Raynaud’s phenomenon. Nat. Commun. 14, 6156 (2023).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  6. Yengo, L. et al. A saturated map of common genetic variants associated with human height. Nature 610, 704–712 (2022).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  7. Abdulle, A. E. et al. Low body weight and involuntary weight loss are associated with Raynaud’s phenomenon in both men and women. Scand. J. Rheumatol. 50, 153–160 (2021).

    Article  CAS  PubMed  Google Scholar 

  8. Nelson, M. R. et al. The support of human genetic evidence for approved drug indications. Nat. Genet. 47, 856–860 (2015).

    Article  CAS  PubMed  Google Scholar 

  9. Ochoa, D. et al. Open Targets Platform: supporting systematic drug-target identification and prioritisation. Nucleic Acids Res. 49, D1302–D1310 (2021).

    Article  CAS  PubMed  Google Scholar 

  10. Coffman, J. D. Raynaud’s phenomenon. An update. Hypertension 17, 593–602 (1991).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK

    Ariane L. Herrick & Gisela Orozco

Authors
  1. Ariane L. Herrick
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gisela Orozco
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ariane L. Herrick.

Ethics declarations

Competing interests

A.L.H. has received consultancy fees from Arena, Boehringer Ingelheim, Camurus, Galderma and Gesynta Pharma, speaker fees from Janssen and research funding from Gesynta Pharma. G.O. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Herrick, A.L., Orozco, G. Raynaud phenomenon: from GWAS to drug repurposing. Nat Rev Rheumatol 20, 139–140 (2024). https://doi.org/10.1038/s41584-024-01076-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41584-024-01076-x

  • Springer Nature Limited

Search

Navigation